• Citer

Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial

par Modi, Shanu;Jacot, William;Iwata, Hiroji;Park, Yeon Hee;Vidal, María Jesus M.;Li, Wei;Tsurutani, Junji;Ueno, Naoto Tada;Zaman, Khalil;Prat, Aleix;Papazisis, Konstantinos;Rugo, Hope H.S.;Yamashita, Toshinari;Harbeck, Nadia;Im, Seock–Ah –A;De Laurentiis, Michelino;Pierga, Jean Yves Ves J.Y.;Wang, Xiaojia;Gombos, Andrea ;Tokunaga, Eriko;Orbegoso Aguilar, Cecilia;Yung, Lotus;Xiao, Feng;Cheng, Yingkai;Cameron, David A
Référence Nature medicine, 31, 12, page (4205-4213)
Publication Publié, 2025-12

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Auteur:	Modi, Shanu; Jacot, William; Iwata, Hiroji; Park, Yeon Hee; Vidal, María Jesus M.; Li, Wei; Tsurutani, Junji; Ueno, Naoto Tada; Zaman, Khalil; Prat, Aleix; Papazisis, Konstantinos; Rugo, Hope H.S.; Yamashita, Toshinari; Harbeck, Nadia; Im, Seock–Ah –A; De Laurentiis, Michelino; Pierga, Jean Yves Ves J.Y.; Wang, Xiaojia; Gombos, Andrea; Tokunaga, Eriko; Orbegoso Aguilar, Cecilia; Yung, Lotus; Xiao, Feng; Cheng, Yingkai; Cameron, David A
Informations sur la publication:	Nature medicine, 31, 12, page (4205-4213)
Statut de publication:	Publié, 2025-12
Sujet CREF:	Biologie
	Sciences bio-médicales et agricoles
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1078-8956
	info:doi/10.1038/s41591-025-03981-4
	info:scp/105018328274
	info:pmid/41062831